NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

ArriVent BioPharma, Inc. (AVBP) Stock Analysis

ArriVent BioPharma, Inc. (AVBP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AVBP

$19.12

+$0.27 (+1.43%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVBP with… →

AVBP Key Statistics

As of Oct 21, 2026
Trading
Open
$19.09
Previous Close
$18.85
Day's Range
18.68–19.44
52-Week Range
11.36–35.83
Volume
1.49M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.35
Valuation
Market Cap
$942.76M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.62
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$166.31M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
49.31M
1-Year Return
−2.40%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
1.01M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AVBP closed at $19.12, −2.40% over 1 year.

ArriVent BioPharma, Inc. (AVBP) has a market capitalization of $942.76M.

In fiscal 2025, AVBP reported revenue of $0.00.

AVBP Stock Return by Calendar Year

ArriVent BioPharma, Inc. (AVBP) return since Jan 2024: what $10,000 became

1 year
$10,000 $9,760
−2.40%
Since Jan 2024
$10,000 $9,560
−4.40%

If you had invested $10,000 in ArriVent BioPharma, Inc. (AVBP) at the close on January 26, 2024, the earliest close on record here, it would have been worth $9,560 at the close on October 21, 2026: −4.40% in total, −1.63% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.97%
2025−24.47%
2024+33.20%

As of October 21, 2026.

AVBP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$166.31M—
2024$0.00−$80.49M—
2023$0.00−$69.33M—
2022$0.00−$36.91M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$177.53M−$166.31M—
2024$0.00—−$94.31M−$80.49M—
2023$0.00—−$74.59M−$69.33M—
2022$0.00—−$36.91M−$36.91M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ArriVent BioPharma, Inc. (AVBP) carries a market capitalisation of $942.76M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 77.

The 52-week range on file runs from $11.36 to $35.83. AVBP last closed at $19.12 on October 21, 2026. That is +$0.27 (+1.43%) against the previous close. The latest close sits 68.31% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $166.31M. Earnings per share on a trailing basis come to −3.62.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.35. Daily returns over the trailing 2 years annualize to a volatility of 64.5%. Over the trailing twelve months the total return is −2.40%. The stored price history starts on January 26, 2024, and the total return since then is −4.40%.

Growth & Income

The record shows no dividend for AVBP.

2026 is still running; the total return is −4.97% year to date. The strongest complete calendar year on file is 2024 at +33.20%; the weakest is 2025 at −24.47%.

Peer Comparison

ArriVent BioPharma, Inc. (AVBP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ArriVent BioPharma, Inc. AVBP $942.76M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. ArriVent BioPharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Visit website →